Generex presents data on its oral insulin spray, metformin gum products at meeting

By Lisa Kerner

Charlotte, N.C., July 26 - Generex Biotechnology Corp. made two poster presentations of clinical data at the 33rd Annual Meeting & Exposition of the Controlled Release Society in Vienna, Austria, related to its proprietary oral insulin spray product, Oral-lyn, and its Metformin Gum, an alternative delivery format for metformin.

The first presentation detailed an ongoing, long-term study of young adults with type 1 diabetes comparing the effects of replacing the lunchtime dose of regular insulin with Generex Oral-lyn given as a split dose before and after lunch.

The second poster reported the results of a clinical trial comparing pharmacokinetic profiles of metformin (used for the treatment of type-2 diabetes mellitus in adults and children) administered by both tablets and by the Metformin Gum product.

Generex said the Metformin Gum displays a pharmacokinetic profile similar to that of the metformin tablets and shows promise as an alternative method of delivering metformin. Metformin Gum is expected to be a companion product for the company's oral insulin spray product.

Toronto-based Generex specializes in the research and development of drug delivery systems and technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.